An analysis of pooled data from the phase 3 ODYSSEY program, including 4915 patients with hypercholesterolemia from 10 phase 3 studies, showed the use of Alirocumab was associated with a reduction in Lp(a)between 23% and 29% according to the drug regimen (alirocumab 75 mg or 150 mg every 2 weeks) [57]. This evidence concerns the gene LPA and familial hypercholesterolemia.